ATE194597T1 - Substituierte salizylsäure zur behandlung von autoimmunkrankheiten - Google Patents

Substituierte salizylsäure zur behandlung von autoimmunkrankheiten

Info

Publication number
ATE194597T1
ATE194597T1 AT92924067T AT92924067T ATE194597T1 AT E194597 T1 ATE194597 T1 AT E194597T1 AT 92924067 T AT92924067 T AT 92924067T AT 92924067 T AT92924067 T AT 92924067T AT E194597 T1 ATE194597 T1 AT E194597T1
Authority
AT
Austria
Prior art keywords
compound
autoimmune diseases
treatment
salicylic acid
substituted salicylic
Prior art date
Application number
AT92924067T
Other languages
English (en)
Inventor
Karl Hubert Agback
Leif Ahrgren
Thomas Berglindh
Martin Haraldsson
Lars-Inge Olsson
Goeran Smedegard
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of ATE194597T1 publication Critical patent/ATE194597T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT92924067T 1991-11-18 1992-11-04 Substituierte salizylsäure zur behandlung von autoimmunkrankheiten ATE194597T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror
PCT/SE1992/000758 WO1993010094A1 (en) 1991-11-18 1992-11-04 Novel substituted salicyclic acids

Publications (1)

Publication Number Publication Date
ATE194597T1 true ATE194597T1 (de) 2000-07-15

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924067T ATE194597T1 (de) 1991-11-18 1992-11-04 Substituierte salizylsäure zur behandlung von autoimmunkrankheiten

Country Status (29)

Country Link
US (3) US5302718A (de)
EP (1) EP0613468B1 (de)
JP (1) JP3259915B2 (de)
KR (1) KR100253748B1 (de)
AT (1) ATE194597T1 (de)
AU (1) AU668528B2 (de)
CA (1) CA2123697C (de)
DE (1) DE69231252T2 (de)
DK (1) DK0613468T3 (de)
EE (1) EE03026B1 (de)
ES (1) ES2149780T3 (de)
FI (1) FI106857B (de)
GR (1) GR3034585T3 (de)
HU (2) HU221476B (de)
IL (1) IL103665A (de)
LT (1) LT3182B (de)
LV (1) LV10246B (de)
MX (1) MX9206647A (de)
MY (1) MY130169A (de)
NO (1) NO300805B1 (de)
NZ (1) NZ244998A (de)
PT (1) PT101068B (de)
RU (1) RU2124501C1 (de)
SE (1) SE9103397D0 (de)
SK (1) SK282080B6 (de)
TW (1) TW304944B (de)
UA (1) UA42869C2 (de)
WO (1) WO1993010094A1 (de)
ZA (1) ZA928864B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
AU7074496A (en) 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
BR9708151A (pt) 1996-02-20 1999-07-27 Bristol Myers Squibb Co Processo para a preparaç o de bifenil isoxazol sulfonamidas
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
EP1093362A1 (de) 1998-06-12 2001-04-25 Ligand Pharmaceuticals Incorporated Verwendung von rxr modulatoren zur behandlung von anti-östrogen-resistent brustkrebs
EP1165472A4 (de) 1999-03-19 2002-11-20 Bristol Myers Squibb Co Verfahren zur herstellung von biphenyl isoxazol
WO2001017942A1 (en) 1999-09-04 2001-03-15 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
US6552225B1 (en) 1999-09-04 2003-04-22 Astrazeneca Ab Chemical compounds
BR0013694A (pt) 1999-09-04 2002-05-21 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto
DE60115414D1 (de) * 2000-04-28 2006-01-05 Univ British Columbia N-heterosubstituierten salicylaten zur behandlung von krebs
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
KR100360342B1 (ko) * 2002-04-19 2002-11-13 박계정 밸런스 머신의 언밸런스 수정위치 및 수정량의 자동 보상방법
EP1661889A4 (de) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co Chemokinrezeptorantagonist und dessen medizinische verwendung
MXPA06007077A (es) * 2003-12-19 2006-08-23 Pfizer Derivados de bencenosulfonilamino-piridin-2-ilo y compuestos relacionados como inhibidores de 11-beta-hidroxi esteroide deshidrogenasa tipo 1 para el tratamiento de diabetes y obesidad.
JP2008504363A (ja) * 2004-06-29 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐ２ｘ７受容体のベンズアミド阻害剤を利用する併用療法
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
AU2007217750A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
MX2010014232A (es) * 2008-06-23 2011-03-25 Astellas Pharma Inc Compuesto de sulfamida o sal del mismo.
EP2677865A4 (de) * 2011-02-23 2015-04-22 Icahn School Med Mount Sinai Hemmer von bromdomänen als genexpressionsmodulatoren
CA2985542C (en) 2015-05-20 2023-10-10 Amgen Inc. Triazole agonists of the apj receptor
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541805B1 (de) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituierte triazole als apj-rezeptoragonisten
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
AU567140B2 (en) * 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
LTIP229A (en) 1994-09-25
SE9103397D0 (sv) 1991-11-18
HUT69723A (en) 1995-09-28
HU211163A9 (en) 1995-10-30
KR100253748B1 (ko) 2000-05-01
CA2123697C (en) 2003-12-09
CA2123697A1 (en) 1993-05-27
PT101068B (pt) 1999-08-31
FI942289L (fi) 1994-05-17
NZ244998A (en) 1995-09-26
MY130169A (en) 2007-06-29
AU668528B2 (en) 1996-05-09
FI942289A0 (fi) 1994-05-17
SK282080B6 (sk) 2001-10-08
NO300805B1 (no) 1997-07-28
FI106857B (fi) 2001-04-30
ZA928864B (en) 1993-05-13
US5302718A (en) 1994-04-12
JPH07501330A (ja) 1995-02-09
ES2149780T3 (es) 2000-11-16
JP3259915B2 (ja) 2002-02-25
DE69231252T2 (de) 2001-03-01
LV10246A (lv) 1994-10-20
DK0613468T3 (da) 2000-10-23
SK54794A3 (en) 1995-02-08
DE69231252D1 (de) 2000-08-17
EE03026B1 (et) 1997-08-15
RU2124501C1 (ru) 1999-01-10
EP0613468A1 (de) 1994-09-07
PT101068A (pt) 1994-02-28
HU221476B (en) 2002-10-28
UA42869C2 (uk) 2001-11-15
NO941799L (de) 1994-06-22
LT3182B (en) 1995-03-27
IL103665A0 (en) 1993-04-04
HU9401391D0 (en) 1994-08-29
EP0613468B1 (de) 2000-07-12
WO1993010094A1 (en) 1993-05-27
NO941799D0 (no) 1994-05-13
US5403930A (en) 1995-04-04
US5556855A (en) 1996-09-17
TW304944B (de) 1997-05-11
MX9206647A (es) 1993-05-01
GR3034585T3 (en) 2001-01-31
AU2958992A (en) 1993-06-15
IL103665A (en) 1997-08-14
LV10246B (en) 1995-04-20

Similar Documents

Publication Publication Date Title
ATE194597T1 (de) Substituierte salizylsäure zur behandlung von autoimmunkrankheiten
RU94028109A (ru) Новые замещенные салициловые кислоты, способ их получения
DK0638071T3 (da) Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR)
BR1100086A (pt) Derivados de fluoralcóxibenzilamino de heterocìclos contendo nitrogênio
CY1110979T1 (el) Παραγωγα κιναζολινης ως αναστολεις αγγειογενεσης και ενδιαμεσες ενωσεις αυτων
FI940414A0 (fi) Kinoliini- tai kinatsoliinijohdannaiset, niiden valmistus ja käyttö
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
BR0311535A (pt) Uso de cianopirrolidinas substituìdas e preparações de combinações contendo as mesmas para o tratamento da hiperlipidemia e doenças associadas
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
DE69418744D1 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
NO305799B1 (no) Nye kinolinderivater, farmas°ytiske preparater inneholdende slike derivater, deres anvendelse samt mellomprodukter

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee